MarketPulse

COPD

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

65+ Pharma Giants Race to Dominate COPD Market with Next-Gen Biologics

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.
AMGNPFESNYAZNUPB+2clinical trialsbiologics
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Respiratory Care Device Market to Double to $47.5B by 2034 on Disease Surge

Global respiratory care devices market projected to grow 8% annually to $47.5B by 2034, driven by chronic disease prevalence and home healthcare demand.
MDTRMDPHGGEHCmarket growthCOPD
BenzingaBenzinga··Vandana Singh

AstraZeneca Splits on HPP Drug as COPD Candidate Advances

AstraZeneca's efzimfotase alfa succeeds in pediatric HPP trials but fails in adults. Meanwhile, tozorakimab meets COPD endpoints across smoker populations.
AZNPhase 3 trialsCOPD
BenzingaBenzinga··Vandana Singh

AstraZeneca Powers Ahead in COPD with Blockbuster Trial Win, Eyes $3-5B Peak Sales

AstraZeneca's tozorakimab shows positive Phase 3 COPD data, reducing exacerbations versus placebo. Stock rises 3.68% premarket; company forecasts $3-5B peak sales.
SNYAZNREGNmonoclonal antibodyPhase 3 trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Apogee CEO Sells $1.5M in Stock Despite 100% Surge; Clinical Data Tells Real Story

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.
APGEbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio to Unveil Extended VIBRANT Trial Data on Verekitug at AAAAI 2026

Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.
UPBPhase 2 clinical trialmonoclonal antibody
The Motley FoolThe Motley Fool··Jonathan Ponciano

Great Point Partners Doubles Down on Apogee Therapeutics With $28M Position

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.
APGEbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Upstream Bio to Present Pipeline Progress at Major Healthcare Conferences

Upstream Bio will present pipeline progress at two March 2026 healthcare conferences, discussing its TSLP receptor antagonist in Phase 2 trials for severe respiratory conditions.
UPBinvestor conferenceverekitug